-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Neuroblastoma is a cancer of immature nerve cells in the sympathetic nervous system
The results of the St.
"I have been treating high-risk neuroblastoma for 30 years, and I have never seen such results in high-risk patients," said Wayne Furman, MD, the first author and corresponding author of the Department of Oncology
Forman said that if this finding is confirmed in a larger, multicenter clinical trial, the immunochemotherapy detailed in this study may become the standard treatment for patients with high-risk diseases
An anti-gd2 monoclonal antibody
Hu14.
Hu14.
The phase II study included hu14.
What is the key?
Dinutuximab is the first anti-gd2 monoclonal antibody approved by the US Food and Drug Administration for the treatment of high-risk neuroblastoma
The dose of hu14.
Forman said: “Because dinuciimab cannot be given at the same dose, an unanswered question is whether the results of the patients in this study are so good because hu14.
Hu14.
Journal Reference :
Wayne L.